Expedia (NASDAQ:EXPE) today had its estimates increased by UBS (NYSE:UBS) following the spinoff of TripAdvisor. A neutral rating with a $13 price target was set.
Shares are higher by about 2.7 percent.
Salix Pharmaceuticals (NASDAQ:SLXP) today had its estimates increased by Goldman Sachs (NYSE:GS) following the issuance of positive Phase III data on its drug for the treatment of opioid-induced constipation. numbers raised at Goldman Sachs. A target price of $46 was set with a neutral rating.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.